PortfoliosLab logoPortfoliosLab logo
AYTU vs. GORO
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

AYTU vs. GORO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Aytu BioPharma, Inc. (AYTU) and Gold Resource Corporation (GORO). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

AYTU vs. GORO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
AYTU
Aytu BioPharma, Inc.
1.54%52.94%-40.14%-24.87%-86.00%-77.42%-38.35%22.41%-98.22%-88.85%
GORO
Gold Resource Corporation
53.38%259.84%-38.80%-75.42%0.20%-45.33%-46.91%39.34%-8.71%-18.75%

Fundamentals

Market Cap

AYTU:

$26.50M

GORO:

$174.40M

EPS

AYTU:

-$2.02

GORO:

-$0.05

PB Ratio

AYTU:

1.87

GORO:

3.96

Total Revenue (TTM)

AYTU:

$62.64M

GORO:

$0.00

Gross Profit (TTM)

AYTU:

$41.34M

GORO:

$26.78M

EBITDA (TTM)

AYTU:

-$17.24M

GORO:

$8.15M

Returns By Period

In the year-to-date period, AYTU achieves a 1.54% return, which is significantly lower than GORO's 53.38% return.


AYTU

1D
-3.30%
1M
-0.00%
YTD
1.54%
6M
41.18%
1Y
127.59%
3Y*
5.63%
5Y*
-55.49%
10Y*

GORO

1D
5.83%
1M
-16.45%
YTD
53.38%
6M
53.01%
1Y
162.07%
3Y*
6.55%
5Y*
-14.41%
10Y*
-5.48%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

AYTU vs. GORO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AYTU
AYTU Risk / Return Rank: 8585
Overall Rank
AYTU Sharpe Ratio Rank: 7575
Sharpe Ratio Rank
AYTU Sortino Ratio Rank: 9191
Sortino Ratio Rank
AYTU Omega Ratio Rank: 8989
Omega Ratio Rank
AYTU Calmar Ratio Rank: 8484
Calmar Ratio Rank
AYTU Martin Ratio Rank: 8484
Martin Ratio Rank

GORO
GORO Risk / Return Rank: 8383
Overall Rank
GORO Sharpe Ratio Rank: 8383
Sharpe Ratio Rank
GORO Sortino Ratio Rank: 8787
Sortino Ratio Rank
GORO Omega Ratio Rank: 7979
Omega Ratio Rank
GORO Calmar Ratio Rank: 8787
Calmar Ratio Rank
GORO Martin Ratio Rank: 8181
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AYTU vs. GORO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Aytu BioPharma, Inc. (AYTU) and Gold Resource Corporation (GORO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


AYTUGORODifference

Sharpe ratio

Return per unit of total volatility

1.09

1.49

-0.40

Sortino ratio

Return per unit of downside risk

3.01

2.60

+0.41

Omega ratio

Gain probability vs. loss probability

1.39

1.29

+0.11

Calmar ratio

Return relative to maximum drawdown

2.83

3.37

-0.54

Martin ratio

Return relative to average drawdown

7.53

6.45

+1.09

AYTU vs. GORO - Sharpe Ratio Comparison

The current AYTU Sharpe Ratio is 1.09, which is comparable to the GORO Sharpe Ratio of 1.49. The chart below compares the historical Sharpe Ratios of AYTU and GORO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


AYTUGORODifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.09

1.49

-0.40

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.65

-0.16

-0.49

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.07

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.36

0.03

-0.39

Correlation

The correlation between AYTU and GORO is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

AYTU vs. GORO - Dividend Comparison

Neither AYTU nor GORO has paid dividends to shareholders.


TTM20252024202320222021202020192018201720162015
AYTU
Aytu BioPharma, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
GORO
Gold Resource Corporation
0.00%0.00%0.00%0.00%2.61%2.78%1.37%0.42%0.50%0.45%0.69%7.23%

Drawdowns

AYTU vs. GORO - Drawdown Comparison

The maximum AYTU drawdown since its inception was -100.00%, roughly equal to the maximum GORO drawdown of -99.48%. Use the drawdown chart below to compare losses from any high point for AYTU and GORO.


Loading graphics...

Drawdown Indicators


AYTUGORODifference

Max Drawdown

Largest peak-to-trough decline

-100.00%

-99.48%

-0.52%

Max Drawdown (1Y)

Largest decline over 1 year

-42.47%

-44.27%

+1.80%

Max Drawdown (5Y)

Largest decline over 5 years

-99.34%

-95.73%

-3.61%

Max Drawdown (10Y)

Largest decline over 10 years

-98.29%

Current Drawdown

Current decline from peak

-100.00%

-94.72%

-5.28%

Average Drawdown

Average peak-to-trough decline

-95.05%

-64.84%

-30.21%

Ulcer Index

Depth and duration of drawdowns from previous peaks

15.93%

23.14%

-7.21%

Volatility

AYTU vs. GORO - Volatility Comparison

The current volatility for Aytu BioPharma, Inc. (AYTU) is 10.33%, while Gold Resource Corporation (GORO) has a volatility of 24.14%. This indicates that AYTU experiences smaller price fluctuations and is considered to be less risky than GORO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


AYTUGORODifference

Volatility (1M)

Calculated over the trailing 1-month period

10.33%

24.14%

-13.81%

Volatility (6M)

Calculated over the trailing 6-month period

38.47%

75.17%

-36.70%

Volatility (1Y)

Calculated over the trailing 1-year period

117.92%

109.49%

+8.43%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

85.84%

92.09%

-6.25%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

190.00%

78.83%

+111.17%

Financials

AYTU vs. GORO - Financials Comparison

This section allows you to compare key financial metrics between Aytu BioPharma, Inc. and Gold Resource Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


-40.00M-20.00M0.0020.00M40.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
15.17M
-48.06M
(AYTU) Total Revenue
(GORO) Total Revenue
Values in USD except per share items

AYTU vs. GORO - Profitability Comparison

The chart below illustrates the profitability comparison between Aytu BioPharma, Inc. and Gold Resource Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-50.0%0.0%50.0%AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
60.0%
-60.4%
Portfolio components
AYTU - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Aytu BioPharma, Inc. reported a gross profit of 9.10M and revenue of 15.17M. Therefore, the gross margin over that period was 60.0%.

GORO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Gold Resource Corporation reported a gross profit of 29.04M and revenue of -48.06M. Therefore, the gross margin over that period was -60.4%.

AYTU - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Aytu BioPharma, Inc. reported an operating income of -1.97M and revenue of 15.17M, resulting in an operating margin of -13.0%.

GORO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Gold Resource Corporation reported an operating income of 28.97M and revenue of -48.06M, resulting in an operating margin of -60.3%.

AYTU - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Aytu BioPharma, Inc. reported a net income of -10.58M and revenue of 15.17M, resulting in a net margin of -69.8%.

GORO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Gold Resource Corporation reported a net income of 18.00M and revenue of -48.06M, resulting in a net margin of -37.5%.